Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 20, 2025. REUTERS/Brendan McDermid/File Photo Wall Street's main indexes declined on Friday as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback